We have carried out overnight measurements of hepatic secretion rate and duodenal output of biliary lipids using a duodenal perfusion technique. We correlated these measurements with the fasting state mass of biliary lipids within the gall bladder on the following morning using a combined nasoduodenal intubation and isotope scanning technique. We studied six gail stone subjects before and during treatment with ursodeoxycholic acid 675 mg/day. Lipid mass within the gail bladder correlated with the corresponding overnight hepatic secretion rate for ali three biliary lipids. During ursodeoxycholic acid treatment, there was an increase in gall bladder bile acid mass without significant change in cholesterol or phospholipid mass. We conclude that the mass of individual biliary lipids within the fasting gall bladder is influenced by overnight hepatic biliary lipid secretion rate; and that the effect of ursodeoxycholic acid (675 mg/day) on cholesterol saturation index of fasting gail bladder bile is mediated via an increase in bile acid mass rather than through a decrease in cholesterol mass within the gall bladder.
Oral administration of ursodeoxycholic acid reduces cholesterol saturation index of fasting gall bladder bile and dissolves gall stones in selected patients.' 2 It is not known whether the effect on cholesterol saturation index is caused by an increase in the absolute mass of bile acid and phospholipid within the gall bladder, or a decrease in cholesterol mass, or a combination of these effects. Only indirect information is available, based on The aim of our study was to clarify the mechanisms involved by measuring the absolute mass of bile acid, cholesterol, and phospholipid within the fasting gall bladder before and during ursodeoxycholic acid treatment. We also studied factors affecting biliary lipid mass by measuring overnight hepatic secretion rates and duodenal output for bile acid, cholesterol, and phospholipid. Thus, we were able to explain the effect of ursodeoxycholic acid in terms of hepatic secretion ('the input') and duodenal output ('the output'), and in terms of lipid mass in the gall bladder ('the resultant').
Methods

SUBJECTS
We studied six subjects (three men and three women, age range 49-70 years, mean (SD) of 61-3 (8-4) years; body weight range 48-90 kg, mean (SD) of 66-2 (14-1) kg) with radiolucent gall stones in radiologically functioning gall bladders, after obtaining written informed consent. Radiation exposure was calculated to be <0 05 rad for the gut and the gall bladder wall in all subjects. The study was approved by the Local Hospital Ethical Committee in September 1981.
EXPERIMENTAL DESIGN
All subjects were studied on and off ursodeoxycholic acid treatment. Four subjects (nos 1-4 in Table I ) were allocated to receive baseline studies first, and two (nos 5 and 6 in Table I ) to receive during treatment studies first. After completion of the baseline studies, the first group was started on treatment and repeat studies were carried out six to eight weeks later. The second group was studied six weeks after starting treatment, and had repeat studies six weeks after stopping it. Treatment consisted of ursodeoxycholic acid (Gipharmex, Milan, Italy) 675 mg/day as a single bedtime dose. When studied during the treatment regimen, the subjects received the ursodeoxycholic acid dose five hours after the evening meal. The dose on a body weight basis ranged from 7 5 to 14 1 mg/kg/day (mean (SD): 10 6 (2 2) mg/kg/day).
CLINICAL PROCEDURE These were as described previously.56 On the day of the study, the fasting subjects were admitted to a clinical investigation ward. A four 12 hours. An aliquot of the aspirate (consistently <5% of the total) was retained for analysis, and the remainder reinfused into the intestine through the distal tube to maintain the enterohepatic circulation of bile acids.
Hepatic biliary lipid secretion This was measured by relating duodenal outputs to the duodenal recovery of indocyanine green which was continuously infused intravenously (iv) during the whole study,8 as described previously.56 By the time duodenal aspiration was started at 6 pm, the indocyanine green iv infusion had been given for the three hour period needed to equilibrate its iv infusion rate with its hepatic output.8
Biliary lipid mass within the gall bladder This was measured as previously described"9 at the end of the duodenal perfusion study. In brief, 5 mCi 9mTc HIDA sodium n-n (2,6-diethylphenlyl-carbamylmethyl iminodiacetate, Amersham plc, Bucks, UK), was injected iv at 3 pm. On the following morning the residual 'Tc HIDA activity in the gall bladder was measured by anterior and posterior abdominal scanning using a gamma camera/computer system (model Sigma 4105/MCS-560, Technicare, USA). The reason for giving 'Tc HIDA the day before the gamma camera study was to enable us to measure its duodenal output during the whole study for simultaneous measurement of absolute gall bladder emptying and filling as reported in a separate paper.5 Data obtained from abdominal gamma camera counting were stored in the computer and later reanalysed using an area of interest facility to outline the gall bladder area as described previously.5 A sample of gall bladder bile was collected after the abdominal gamma camera study by stimulating gall bladder contraction with intravenous cholecystokinin (Boots, UK) for measurement of biliary lipid mass as described previously. Table II) There was a large variation between individual subjects before treatment for biliary lipid mass in the gall bladder and for hepatic secretion rates. Despite these variations in baseline measurements, and despite the differences in the daily ursodeoxycholic acid dose/kg body weight administered to individual subjects, changes observed during ursodeoxycholic acid treatment were consistent in individual subjects. Cholesterol saturation index of fasting gall bladder bile was reduced in each individual during ursodeoxycholic acid administration, and the mean value fell from 1-68 (0-55) to 0-93 (0-29) (p<0O02). Gall bladder bile acid mass increased in five subjects, the mean value increasing from 3-8 (1-8) to 6-3 (3-2) mmol (p<0-02) during ursodeoxycholic acid administration. Gall bladder phospholipid mass increased in four subjects, but the mean value did not change significantly (1-5 (1-0) We have previously found a significant relationship between gall bladder cholesterol mass and saturation index in a homogeneous group of 10 young male non-obese healthy volunteers.9 We failed to find a relationship in the six gall stone subjects studied here. This discrepancy may be partly explained by the observation that, by contrast with our previous study on healthy volunteers, this group of subjects was not homogeneous in relation to sex, body weight, and age. These factors are all known to influence cholesterol secretion, and they may have also influenced cholesterol mass in the gall bladder to a different extent in different subjects. The magnitude of the effect of ursodeoxycholic acid on gall bladder bile acid mass (an increase of 2 5 mmol) is greater than that which can be attributed to the bedtime dose of ursodeoxycholic acid (approximately 1 mmol). Expansion of the bile acid pool has been reported by Nilsell et al3 and by Von Bergmann et al4 after chronic administration of a similar dose of ursodeoxycholic acid, and this may explain the size of the increase in bile acid mass observed during treatment. A significant correlation has been previously reported between bile acid pool size and bile acid mass within the gall bladder in ten healthy male volunteers.9 The increase in bile acid mass during ursodeoxycholic acid treatment was accompanied by a non-significant trend for phospholipid mass. This increase in phospholipid mass occurred in only four subjects (mean increase 53% compared with 66% for bile acid). By contrast, there was absolutely no change in cholesterol mass (Fig 2) . This latter finding could not have been predicted on the basis of biliary lipid secretion measurements, which have consistently shown a reduction in cholesterol secretion during ursodeoxycholic acid treatment. 34 An advantage of the technique used in this study was that it enabled us to distinguish the mechanism involved in the reduced cholesterol saturation index in hepatic bile from that involved in gall bladder bile during ursodeoxycholic acid administration. That the two mechanisms are different is clearly shown by this study. Our results for ursodeoxycholic acid indicate that when this is given at bedtime, the reduction in cholesterol saturation index of hepatic bile involves an increase in bile acid secretion rate together with a decrease in cholesterol secretion rate (Table I) . By contrast, the reduction in cholesterol saturation index of fasting gall bladder bile involves an increase in bile acid mass in the gall bladder and no reduction in cholesterol mass (Fig 2) . Although there is an increase in bile acid for both hepatic secretion rate and gall bladder mass, the relative increase was greater for the latter (approximately 85%) than for the former (approximately 35%), implying increased diversion of hepatic bile into the gall bladder. This increased diversion provides an explanation for the fact that the decrease in cholesterol secretion rate was not accompanied by a decrease in cholesterol mass in the gall bladder.
The fact that ursodeoxycholic acid treatment increased gall bladder storage of biliary lipids is consistent with our finding that hepatic bile acid secretion rate ('the input') increased during treatment without significant increase in duodenal bile acid output ('the output'). This may be explained by the observation of Forgacs et all9 that gall bladder emptying is decreased in gallstone patients receiving ursodeoxycholic acid, consistent with our finding of an enhancement of gall bladder storage ('the resultant').
